DrugChatter: Half life of eliquis?
What is the half-life of Eliquis? The half-life of Eliquis (apixaban) is approximately 8-15 hours. However, this value can… https://www.Drugchatter.com/chat/1212/half-life-of-eliquis/
What is the half-life of Eliquis? The half-life of Eliquis (apixaban) is approximately 8-15 hours. However, this value can… https://www.Drugchatter.com/chat/1212/half-life-of-eliquis/
Ist das Patent fr Carboplatin schon abgelaufen? Carboplatin is an older chemotherapy drug, and its core manufacturing… https://www.Drugchatter.com/chat/56649/carboplatin-patent-abgelaufen/
What is meloxicam API? Meloxicam API usually means the active pharmaceutical ingredient (API)… https://www.Drugchatter.com/chat/45279/meloxicam-api/
What patent covers Trintellix (vortioxetine) and when does it expire? Trintellixs active ingredient is vortioxetine…. https://www.Drugchatter.com/chat/25888/trintellix-patent/
Does Absorica (isotretinoin) usually get covered by insurance? Coverage for Absorica depends on the patients specific… https://www.Drugchatter.com/chat/9646/is-absorica-covered-by-insurance/
Tagrisso is manufactured by AstraZeneca [1]. What is Tagrisso used for? Tagrisso (osimertinib) is a targeted therapy used… https://www.Drugchatter.com/chat/9051/tagrisso-maker/
What ingredients are in anastrozole tablets (and what do they do)? Anastrozole is the active ingredient in medicines used… https://www.Drugchatter.com/chat/24199/anastrozole-ingredients/
When does the Vyndaqel patent expire? I cant give a specific expiry date for Vyndaqel from the information… https://www.Drugchatter.com/chat/4392/vyndaqel-patente/
Whats the price of isoniazid (Dow) right now? I cant determine the current cost of Dow isoniazid… https://www.Drugchatter.com/chat/25170/dow-isoniazid-cost/
Pharma IP isnt being defeated by courts. Its being defeated by ignorance.
A lot of people think the real battlefield in pharma intellectual property is a courtroomPTAB panels, Federal Circuit arguments, injunctions, and the occasional blockbuster settl…
Data Beats Capital: Why the Real Challenger in Pharma IP Is the One Who Knows More Read Post »
Get new actionable insights and updates from BiotechBlog